Basic HTML Version
128
SCIENTIFIC REPORT 2012
Title:
Evaluation of the clinical utility of a standardized dose reduction protocol
in patients with axial spondylitis (EA) in persistent clinical remission in treatment with
TNF antagonists: Multicenter, open, controlled, and randomized study.
Promotor
: Spanish Society of Clinical Famacology and Spanish Society of Rheumatology.
Principal Investigator:
Jordi Gratacós Masmitjà.
Title:
Phase 3 study, multicenter, randomized, double-blind, placebo-controlled, of
parallel groups to evaluate the efficacy and safety of Apremilast (CC-10004) in the
treatment of active ankylosing spondylitis.
District Attorney:
Celgene Corporation.
Principal Investigator:
Jordi Gratacós Masmitjà.
Title:
Phase III study, multicenter, randomized, double-blind, placebo-controlled
subcutaneous secukinumab in pre-filled syringes to demonstrate efficacy at 16 weeks
and evaluate long-term efficacy, safety, and tolerability, up to 5 years, in patients with
Active ankylosing spondylitis.
District Attorney:
Novartis Farmacéutica SA.
Principal Investigator:
Jordi Gratacós Masmitjà.
Title:
Observational epidemiological study to evaluate retention in the treatment of
patients with moderate to severe psoriasis in clinical practice. Study SAHARA.
District Attorney:
JANSSEN-CILAG SA
Principal Investigator:
Lorena Leal Canosa.
Title:
Study on obesity and cardiovascular risk factors in patients with
psoriasis in systemic treatment.
District Attorney:
Merck Sharp & Dohme de España SA
Principal Investigator:
Jesus Luelmo Aguilar.
Title:
Optimization of outpatient care with mild to moderate psoriasis
newly created "Topical Treatment Optimization Program" - an international study
using Daivobet® Gel (PSO-TOP).
District Attorney:
Professor Dr. Kristian Reich.
Principal Investigator:
Jesus Luelmo Aguilar.